S2 Episode 4: JAK Inhibitors: Too Many Choices or Not Enough?
Join Drs Tania Jain and Prithviraj Bose as they discuss the available JAK inhibitors and how they use them to treat myelofibrosis.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002056. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/32903304/
You Really Got a Hold on Me https://ashpublications.org/ashclinicalnews/news/6493/You-Really-Got-a-Hold-on-Me
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/22375971/
Overall Survival in the SIMPLIFY-1 and SIMPLIFY-2 Phase 3 Trials of Momelotinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35869266/
Biological Basis for Efficacy of Activin Receptor Ligand Traps in Myelodysplastic Syndromes https://pubmed.ncbi.nlm.nih.gov/31961337/
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (ODYSSEY) https://clinicaltrials.gov/study/NCT06517875
Biology and Therapeutic Targeting of Molecular Mechanisms in MPNs https://pubmed.ncbi.nlm.nih.gov/36534936/
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL) https://clinicaltrials.gov/study/NCT03627403
Selinexor Plus Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis: SENTRY Phase 3 Study Design https://pubmed.ncbi.nlm.nih.gov/39911057/
EHA 2023, Abstract 210: An Open-Label, Global, Phase (Ph) 1b/2 Study Adding Navtemadlin (Nvtm) to Ruxolitinib (Rux) in Patients (Pts) With Primary or Secondary Myelofibrosis (Mf) Who Have a Suboptimal Response to Rux https://library.ehaweb.org/eha/2023/eha2023-congress/387910/john.mascarenhas.an.open-label.global.phase.28ph29.1b.2.study.adding.navtemadlin.html
Imetelstat in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK Inhibitor: IMpactMF Phase III Study Design https://pubmed.ncbi.nlm.nih.gov/35510486/
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/26175413/
Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose With Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV) https://ashpublications.org/blood/article/144/Supplement%201/4568/533799/Ropeginterferon-Alfa-2b-ROPEG-and-Peginterferon
The Characteristics of CALR Mutations in Myeloproliferative Neoplasms: A Clinical Experience From a Tertiary Care Center in Qatar and a Literature Review https://pubmed.ncbi.nlm.nih.gov/38804886/
Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis: A Randomized Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/40065169/
TRANSFORM-1 Trial of Navitoclax in Combination With Ruxolitinib for Myelofibrosis Met Primary but Not Secondary Endpoint https://ashpublications.org/ashclinicalnews/news/7630/TRANSFORM-1-Trial-of-Navitoclax-in-Combination
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/34138638/
Efficacy and Safety of Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib (FREEDOM2): Results From a Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/39265613/
Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib: An Updated Analysis of the JAKARTA2 Study Using Stringent Criteria for Ruxolitinib Failure https://pubmed.ncbi.nlm.nih.gov/32129512/
Impact of TP53 on Outcome of Patients With Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation https://pubmed.ncbi.nlm.nih.gov/36940410/
SURPASS-ET: Phase III Study of Ropeginterferon Alfa-2b Versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia https://pubmed.ncbi.nlm.nih.gov/35924546/
EXCEED-ET: A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS7088
Ropeginterferon alfa-2b Versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-inferiority, Phase 3 Trial and Its Extension Study https://pubmed.ncbi.nlm.nih.gov/32014125/
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/37126762/
